Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 404
- Registration Number
- NCT00379288
Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-09-20
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 127
- Registration Number
- NCT00378378
The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 36
- Registration Number
- NCT00359138
The Effects of Mometasone Furoate Nasal Spray in Subjects With Sleep-disordered Breathing (SDB) Associated With Perennial Allergic Rhinitis (Study P04726)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 30
- Registration Number
- NCT00359216
Mometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhinitis (Study P04608) (COMPLETED)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 401
- Registration Number
- NCT00358527
Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 496
- Registration Number
- NCT00338260
Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1771
- Registration Number
- NCT00337675
TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-05-22
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1496
- Registration Number
- NCT00328523
Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 22
- Registration Number
- NCT00319449
Effects of Loratadine/Montelukast vs Pseudoephedrine and Placebo in Patients With Seasonal Allergic Rhinitis (Study P04095) (COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1095
- Registration Number
- NCT00319995
© Copyright 2024. All Rights Reserved by MedPath